Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Current Status Of The Prediction For Radio-iodine Refractory Thyroid Cancer: A Narrative Review

Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review

Yuhua Wang1,2, Xiurong Lu1,3, Haiyan Liu1,4,5

  • 1Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, Shanxi, China.

Frontiers in Endocrinology
|October 30, 2024

Related Experiment Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

483
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

389

View abstract on PubMed

Summary
This summary is machine-generated.

Predicting radio-iodine refractory thyroid cancer (RAIR) is crucial as its prognosis is poor. Recent developments identify demographic, clinicopathological, serological, and imaging factors that influence RAIR occurrence, aiding early detection and management.

Area of Science:

  • Oncology
  • Nuclear Medicine

Background:

  • Differentiated thyroid cancers generally have a good prognosis.
  • Radio-iodine refractory thyroid cancer (RAIR) presents a poor prognosis with low survival rates.
  • Current therapeutic options for RAIR are limited and possess low efficacy.

Purpose of the Study:

  • To review recent advancements in factors influencing and predicting the development of RAIR.
  • To consolidate understanding of predictors for RAIR in thyroid cancer patients.

Main Methods:

  • Review of recent literature on RAIR prediction.
  • Analysis of variables including demographic characteristics, tumor clinicopathology, serology, disease characteristics, and PET/CT findings.
  • Evaluation of multivariate prediction models and their derived cut-off values.
Keywords:
PET/CTdifferentiated thyroid cancerpredictionradio-iodine refractory

Related Experiment Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

483
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

389

Main Results:

  • Multiple factors, such as demographic data, tumor pathology, serological markers, and PET/CT results, are identified as independent predictors of RAIR.
  • Multivariate prediction models incorporating these factors demonstrate effectiveness in predicting RAIR onset.
  • Current predictive models are primarily based on retrospective data.

Conclusions:

  • Various factors significantly influence the development of RAIR.
  • Established prediction models can effectively forecast RAIR onset.
  • Prospective studies are essential to validate the findings of current retrospective RAIR prediction models.
radioactive iodine therapy